SunTrust Banks Equities Analysts Cut Earnings Estimates for Eli Lilly and Company (NYSE:LLY)
Eli Lilly and Company (NYSE:LLY) – Investment analysts at SunTrust Banks reduced their Q2 2017 earnings estimates for Eli Lilly and in a research report issued to clients and investors on Monday. SunTrust Banks analyst J. Boris now expects that the company will post earnings per share of $1.06 for the quarter, down from their prior estimate of $1.07. SunTrust Banks also issued estimates for Eli Lilly and’s FY2018 earnings at $4.42 EPS.
Eli Lilly and (NYSE:LLY) last posted its quarterly earnings results on Tuesday, April 25th. The company reported $0.98 EPS for the quarter, topping the Zacks’ consensus estimate of $0.96 by $0.02. The firm had revenue of $5.23 billion for the quarter, compared to analysts’ expectations of $5.22 billion. Eli Lilly and had a net margin of 10.13% and a return on equity of 26.64%. The business’s revenue for the quarter was up 7.5% on a year-over-year basis. During the same period in the prior year, the business posted $0.83 earnings per share.
COPYRIGHT VIOLATION NOTICE: This piece of content was posted by American Banking News and is the sole property of of American Banking News. If you are viewing this piece of content on another website, it was copied illegally and reposted in violation of U.S. and international trademark & copyright law. The correct version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/07/18/suntrust-banks-equities-analysts-cut-earnings-estimates-for-eli-lilly-and-company-nyselly.html.
LLY has been the subject of several other reports. BidaskClub raised Eli Lilly and from a “sell” rating to a “hold” rating in a research report on Wednesday, June 14th. Barclays PLC lifted their target price on Eli Lilly and from $85.00 to $90.00 and gave the company an “overweight” rating in a research report on Tuesday, July 4th. Jefferies Group LLC reaffirmed a “buy” rating and issued a $96.00 target price (up from $93.00) on shares of Eli Lilly and in a research report on Thursday, July 13th. Citigroup Inc. lifted their target price on Eli Lilly and from $92.00 to $100.00 and gave the company a “buy” rating in a research report on Wednesday, April 19th. Finally, Morgan Stanley downgraded Eli Lilly and from an “overweight” rating to an “equal weight” rating and set a $82.00 target price for the company. in a research report on Monday, April 17th. Two analysts have rated the stock with a sell rating, six have given a hold rating and twelve have given a buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average target price of $87.75.
Eli Lilly and (NYSE:LLY) opened at 83.64 on Tuesday. The stock has a 50 day moving average of $80.49 and a 200-day moving average of $79.95. The company has a market capitalization of $88.35 billion, a PE ratio of 40.44 and a beta of 0.35. Eli Lilly and has a 12-month low of $64.18 and a 12-month high of $86.72.
Large investors have recently modified their holdings of the stock. Vanguard Group Inc. boosted its stake in shares of Eli Lilly and by 3.3% in the first quarter. Vanguard Group Inc. now owns 68,597,006 shares of the company’s stock worth $5,769,694,000 after buying an additional 2,181,701 shares in the last quarter. BlackRock Inc. boosted its stake in shares of Eli Lilly and by 2,628.5% in the first quarter. BlackRock Inc. now owns 62,260,488 shares of the company’s stock worth $5,236,731,000 after buying an additional 59,978,664 shares in the last quarter. State Street Corp boosted its stake in shares of Eli Lilly and by 1.6% in the first quarter. State Street Corp now owns 42,363,935 shares of the company’s stock worth $3,563,230,000 after buying an additional 651,424 shares in the last quarter. Geode Capital Management LLC boosted its stake in shares of Eli Lilly and by 8.4% in the first quarter. Geode Capital Management LLC now owns 9,103,975 shares of the company’s stock worth $764,597,000 after buying an additional 708,597 shares in the last quarter. Finally, Norges Bank purchased a new stake in shares of Eli Lilly and during the fourth quarter worth $658,856,000. Institutional investors own 75.47% of the company’s stock.
In other Eli Lilly and news, SVP Enrique A. Conterno sold 25,000 shares of the business’s stock in a transaction that occurred on Thursday, May 4th. The stock was sold at an average price of $82.76, for a total value of $2,069,000.00. Following the completion of the sale, the senior vice president now owns 114,217 shares in the company, valued at $9,452,598.92. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, major shareholder Lilly Endowment Inc sold 210,000 shares of the business’s stock in a transaction that occurred on Thursday, June 22nd. The shares were sold at an average price of $84.43, for a total value of $17,730,300.00. Following the completion of the sale, the insider now owns 124,265,804 shares of the company’s stock, valued at approximately $10,491,761,831.72. The disclosure for this sale can be found here. Insiders sold 474,733 shares of company stock valued at $39,634,487 over the last ninety days. 0.20% of the stock is currently owned by corporate insiders.
The firm also recently declared a quarterly dividend, which will be paid on Friday, September 8th. Investors of record on Tuesday, August 15th will be issued a $0.52 dividend. This represents a $2.08 dividend on an annualized basis and a yield of 2.49%. The ex-dividend date of this dividend is Friday, August 11th. Eli Lilly and’s dividend payout ratio (DPR) is 100.48%.
About Eli Lilly and
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.